Quick Answer
Kodiak Sciences Inc. reported Net Income of -$229.97 million for fiscal year 2025.
Kodiak Sciences Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$229.97M -30.5% |
-$176.21M +32.4% |
-$260.49M +22.0% |
-$333.82M -25.0% |
-$266.99M -100.6% |
-$133.10M -181.0% |
| Diluted EPS | -$4.32 -29.0% |
-$3.35 +32.6% |
-$4.97 +22.2% |
-$6.39 -23.8% |
-$5.16 -77.3% |
-$2.91 |
| Total Assets | $351.53M +4.8% |
$335.58M -30.0% |
$479.37M -28.1% |
$666.63M -26.3% |
$904.22M -15.3% |
$1.07B +197.4% |
| Cash and Equivalents | $209.86M +24.9% |
$168.07M -41.1% |
$285.51M +49.9% |
$190.43M -74.0% |
$731.51M -22.5% |
$944.40M +345.9% |
| Stockholders Equity | $157.38M +4.7% |
$150.29M -43.5% |
$265.78M -39.1% |
$436.17M -34.2% |
$663.32M -22.9% |
$860.75M +149.2% |
| R&D Expense | $182.37M +44.6% |
$126.09M -38.9% |
$206.30M -22.9% |
$267.59M +23.1% |
$217.34M +102.4% |
$107.39M +186.3% |
| Operating Income | -$234.39M -25.4% |
-$186.85M +32.6% |
-$277.32M +18.8% |
-$341.38M -27.8% |
-$267.05M -96.4% |
-$136.01M -176.5% |
| Shares Outstanding | 61.76M +17.1% |
52.73M +0.4% |
52.51M +0.3% |
52.33M +1.0% |
51.83M +1.4% |
51.11M +15.1% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$61.46M | -39.8% | -13.2% |
| Diluted EPS | September 30, 2025 | -$1.16 | -38.1% | -12.6% |
| Total Assets | September 30, 2025 | $218.07M | -41.5% | -15.1% |
| Cash and Equivalents | September 30, 2025 | $72.04M | -63.6% | -30.8% |
| Stockholders Equity | September 30, 2025 | $23.69M | -87.2% | -66.3% |
| R&D Expense | September 30, 2025 | $50.48M | +58.3% | +18.0% |
| Operating Income | September 30, 2025 | -$62.35M | -33.7% | -12.3% |
| Shares Outstanding | September 30, 2025 | 53.00M | +0.7% | +0.3% |
- Kodiak Sciences Inc. reported Net Income of -$229.97 million for fiscal year 2025.
- Kodiak Sciences Inc. showed a decrease of -30.5% in Net Income compared to the prior fiscal year.
- Kodiak Sciences Inc. reported Diluted EPS of $4.32 per share (loss) for fiscal year 2025.
- Kodiak Sciences Inc. showed a decrease of -29.0% in Diluted EPS compared to the prior fiscal year.
- Kodiak Sciences Inc. reported Total Assets of $351.53 million for fiscal year 2025.
- Kodiak Sciences Inc. showed an increase of +4.8% in Total Assets compared to the prior fiscal year.
- Kodiak Sciences Inc. reported Cash and Equivalents of $209.86 million for fiscal year 2025.
- Kodiak Sciences Inc. showed an increase of +24.9% in Cash and Equivalents compared to the prior fiscal year.
- Kodiak Sciences Inc. reported Stockholders Equity of $157.38 million for fiscal year 2025.
- Kodiak Sciences Inc. showed an increase of +4.7% in Stockholders Equity compared to the prior fiscal year.
- Kodiak Sciences Inc. reported R&D Expense of $182.37 million for fiscal year 2025.
- Kodiak Sciences Inc. showed an increase of +44.6% in R&D Expense compared to the prior fiscal year.
- Kodiak Sciences Inc. reported Operating Income of -$234.39 million for fiscal year 2025.
- Kodiak Sciences Inc. showed a decrease of -25.4% in Operating Income compared to the prior fiscal year.
- Kodiak Sciences Inc. reported Shares Outstanding of 61.76 million shares for fiscal year 2025.
- Kodiak Sciences Inc. showed an increase of +17.1% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: